WO2022149647A1 - 트리아졸로피라진 유도체 화합물을 유효성분으로 하는 약학적 조성물의 태블릿정의 제조방법 - Google Patents
트리아졸로피라진 유도체 화합물을 유효성분으로 하는 약학적 조성물의 태블릿정의 제조방법 Download PDFInfo
- Publication number
- WO2022149647A1 WO2022149647A1 PCT/KR2021/000759 KR2021000759W WO2022149647A1 WO 2022149647 A1 WO2022149647 A1 WO 2022149647A1 KR 2021000759 W KR2021000759 W KR 2021000759W WO 2022149647 A1 WO2022149647 A1 WO 2022149647A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- composition
- binder
- tablet formulation
- disintegrant
- excipient
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 27
- -1 triazolopyrazine derivative compound Chemical class 0.000 title claims description 5
- 239000004480 active ingredient Substances 0.000 title description 10
- 239000008194 pharmaceutical composition Substances 0.000 title description 7
- 239000000203 mixture Substances 0.000 claims abstract description 29
- CJGGKSPGRJHZNP-UHFFFAOYSA-N 2h-triazolo[4,5-b]pyrazine Chemical class C1=CN=C2NN=NC2=N1 CJGGKSPGRJHZNP-UHFFFAOYSA-N 0.000 claims abstract description 27
- 239000011230 binding agent Substances 0.000 claims abstract description 22
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 22
- 239000007884 disintegrant Substances 0.000 claims abstract description 19
- 239000007916 tablet composition Substances 0.000 claims abstract description 14
- 239000008187 granular material Substances 0.000 claims abstract description 10
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 claims abstract description 9
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims abstract description 7
- 229930195725 Mannitol Natural products 0.000 claims abstract description 7
- 239000000594 mannitol Substances 0.000 claims abstract description 7
- 235000010355 mannitol Nutrition 0.000 claims abstract description 7
- 239000000126 substance Substances 0.000 claims abstract description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 16
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 9
- 239000011248 coating agent Substances 0.000 claims description 9
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 9
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 9
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 9
- 238000002156 mixing Methods 0.000 claims description 9
- 238000004519 manufacturing process Methods 0.000 claims description 8
- 201000010099 disease Diseases 0.000 claims description 7
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 claims description 6
- 238000000576 coating method Methods 0.000 claims description 6
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims description 5
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 5
- 229920001983 poloxamer Polymers 0.000 claims description 5
- 229920002785 Croscarmellose sodium Polymers 0.000 claims description 4
- 239000002202 Polyethylene glycol Substances 0.000 claims description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical group O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 4
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 4
- 229940075614 colloidal silicon dioxide Drugs 0.000 claims description 4
- MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 claims description 4
- 229920001223 polyethylene glycol Polymers 0.000 claims description 4
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims description 4
- 239000008109 sodium starch glycolate Substances 0.000 claims description 4
- 229920003109 sodium starch glycolate Polymers 0.000 claims description 4
- 229940079832 sodium starch glycolate Drugs 0.000 claims description 4
- 229940045902 sodium stearyl fumarate Drugs 0.000 claims description 4
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 claims description 3
- OKMWKBLSFKFYGZ-UHFFFAOYSA-N 1-behenoylglycerol Chemical compound CCCCCCCCCCCCCCCCCCCCCC(=O)OCC(O)CO OKMWKBLSFKFYGZ-UHFFFAOYSA-N 0.000 claims description 3
- BDKLKNJTMLIAFE-UHFFFAOYSA-N 2-(3-fluorophenyl)-1,3-oxazole-4-carbaldehyde Chemical compound FC1=CC=CC(C=2OC=C(C=O)N=2)=C1 BDKLKNJTMLIAFE-UHFFFAOYSA-N 0.000 claims description 3
- 229920002261 Corn starch Polymers 0.000 claims description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 3
- YIKYNHJUKRTCJL-UHFFFAOYSA-N Ethyl maltol Chemical compound CCC=1OC=CC(=O)C=1O YIKYNHJUKRTCJL-UHFFFAOYSA-N 0.000 claims description 3
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 claims description 3
- 229930006000 Sucrose Natural products 0.000 claims description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 3
- VJHCJDRQFCCTHL-UHFFFAOYSA-N acetic acid 2,3,4,5,6-pentahydroxyhexanal Chemical compound CC(O)=O.OCC(O)C(O)C(O)C(O)C=O VJHCJDRQFCCTHL-UHFFFAOYSA-N 0.000 claims description 3
- 239000000783 alginic acid Substances 0.000 claims description 3
- 235000010443 alginic acid Nutrition 0.000 claims description 3
- 229920000615 alginic acid Polymers 0.000 claims description 3
- 229960001126 alginic acid Drugs 0.000 claims description 3
- 150000004781 alginic acids Chemical class 0.000 claims description 3
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims description 3
- 239000008120 corn starch Substances 0.000 claims description 3
- 229940099112 cornstarch Drugs 0.000 claims description 3
- 229960005168 croscarmellose Drugs 0.000 claims description 3
- 229960000913 crospovidone Drugs 0.000 claims description 3
- 239000001767 crosslinked sodium carboxy methyl cellulose Substances 0.000 claims description 3
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 claims description 3
- GXGAKHNRMVGRPK-UHFFFAOYSA-N dimagnesium;dioxido-bis[[oxido(oxo)silyl]oxy]silane Chemical compound [Mg+2].[Mg+2].[O-][Si](=O)O[Si]([O-])([O-])O[Si]([O-])=O GXGAKHNRMVGRPK-UHFFFAOYSA-N 0.000 claims description 3
- 229940093503 ethyl maltol Drugs 0.000 claims description 3
- 229940049654 glyceryl behenate Drugs 0.000 claims description 3
- 229940075507 glyceryl monostearate Drugs 0.000 claims description 3
- 238000005469 granulation Methods 0.000 claims description 3
- 230000003179 granulation Effects 0.000 claims description 3
- 239000000391 magnesium silicate Substances 0.000 claims description 3
- 229940099273 magnesium trisilicate Drugs 0.000 claims description 3
- 229910000386 magnesium trisilicate Inorganic materials 0.000 claims description 3
- 235000019793 magnesium trisilicate Nutrition 0.000 claims description 3
- 229960001855 mannitol Drugs 0.000 claims description 3
- 229920000609 methyl cellulose Polymers 0.000 claims description 3
- 239000001923 methylcellulose Substances 0.000 claims description 3
- 235000010981 methylcellulose Nutrition 0.000 claims description 3
- 229960002900 methylcellulose Drugs 0.000 claims description 3
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 claims description 3
- 229960000502 poloxamer Drugs 0.000 claims description 3
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 claims description 3
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 claims description 3
- 235000017281 sodium acetate Nutrition 0.000 claims description 3
- 229940087562 sodium acetate trihydrate Drugs 0.000 claims description 3
- 239000000600 sorbitol Substances 0.000 claims description 3
- 229960002920 sorbitol Drugs 0.000 claims description 3
- 239000005720 sucrose Substances 0.000 claims description 3
- 239000000454 talc Substances 0.000 claims description 3
- 229910052623 talc Inorganic materials 0.000 claims description 3
- 229940033134 talc Drugs 0.000 claims description 3
- 235000012222 talc Nutrition 0.000 claims description 3
- 206010009944 Colon cancer Diseases 0.000 claims description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 2
- 206010033128 Ovarian cancer Diseases 0.000 claims description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 2
- 206010060862 Prostate cancer Diseases 0.000 claims description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 2
- 208000006265 Renal cell carcinoma Diseases 0.000 claims description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 2
- 229940105329 carboxymethylcellulose Drugs 0.000 claims description 2
- 206010017758 gastric cancer Diseases 0.000 claims description 2
- 201000007270 liver cancer Diseases 0.000 claims description 2
- 208000014018 liver neoplasm Diseases 0.000 claims description 2
- 201000005202 lung cancer Diseases 0.000 claims description 2
- 208000020816 lung neoplasm Diseases 0.000 claims description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 2
- 201000002528 pancreatic cancer Diseases 0.000 claims description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 2
- 208000015347 renal cell adenocarcinoma Diseases 0.000 claims description 2
- 201000011549 stomach cancer Diseases 0.000 claims description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims 2
- 229920002472 Starch Polymers 0.000 claims 2
- 239000008101 lactose Substances 0.000 claims 2
- 229960001375 lactose Drugs 0.000 claims 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims 2
- 229940069328 povidone Drugs 0.000 claims 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims 2
- 239000008107 starch Substances 0.000 claims 2
- 229940032147 starch Drugs 0.000 claims 2
- 235000019698 starch Nutrition 0.000 claims 2
- 229960004793 sucrose Drugs 0.000 claims 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 claims 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims 1
- 239000002552 dosage form Substances 0.000 claims 1
- 238000004898 kneading Methods 0.000 claims 1
- 229940080313 sodium starch Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 abstract description 18
- 229940079593 drug Drugs 0.000 abstract description 17
- 238000002360 preparation method Methods 0.000 abstract description 2
- 239000002994 raw material Substances 0.000 abstract 1
- 238000004090 dissolution Methods 0.000 description 12
- 239000000243 solution Substances 0.000 description 11
- 208000035475 disorder Diseases 0.000 description 9
- 150000001875 compounds Chemical class 0.000 description 8
- 230000000694 effects Effects 0.000 description 6
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 4
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 4
- 230000003463 hyperproliferative effect Effects 0.000 description 4
- 238000013268 sustained release Methods 0.000 description 4
- 239000012730 sustained-release form Substances 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 239000013583 drug formulation Substances 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 description 2
- 102000003745 Hepatocyte Growth Factor Human genes 0.000 description 2
- 108090000100 Hepatocyte Growth Factor Proteins 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 206010052779 Transplant rejections Diseases 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 239000001099 ammonium carbonate Substances 0.000 description 2
- 235000012501 ammonium carbonate Nutrition 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 230000012292 cell migration Effects 0.000 description 2
- 238000013270 controlled release Methods 0.000 description 2
- 238000007865 diluting Methods 0.000 description 2
- 238000007922 dissolution test Methods 0.000 description 2
- 238000012377 drug delivery Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- JVGVDSSUAVXRDY-UHFFFAOYSA-N 3-(4-hydroxyphenyl)lactic acid Chemical compound OC(=O)C(O)CC1=CC=C(O)C=C1 JVGVDSSUAVXRDY-UHFFFAOYSA-N 0.000 description 1
- 206010000050 Abdominal adhesions Diseases 0.000 description 1
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- SGHZXLIDFTYFHQ-UHFFFAOYSA-L Brilliant Blue Chemical compound [Na+].[Na+].C=1C=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C(=CC=CC=2)S([O-])(=O)=O)C=CC=1N(CC)CC1=CC=CC(S([O-])(=O)=O)=C1 SGHZXLIDFTYFHQ-UHFFFAOYSA-L 0.000 description 1
- GPXJKVFRKZAYCC-LBPRGKRZSA-N Calacone Natural products O=C1[C@@H](C)CCC(C(C)C)=C1CCC(=C)C GPXJKVFRKZAYCC-LBPRGKRZSA-N 0.000 description 1
- 206010063209 Chronic allograft nephropathy Diseases 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 description 1
- 206010012689 Diabetic retinopathy Diseases 0.000 description 1
- 208000010412 Glaucoma Diseases 0.000 description 1
- 206010018364 Glomerulonephritis Diseases 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 229920003081 Povidone K 30 Polymers 0.000 description 1
- 229920003082 Povidone K 90 Polymers 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 206010038933 Retinopathy of prematurity Diseases 0.000 description 1
- 206010038934 Retinopathy proliferative Diseases 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 239000004141 Sodium laurylsulphate Substances 0.000 description 1
- 208000034841 Thrombotic Microangiopathies Diseases 0.000 description 1
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000007963 capsule composition Substances 0.000 description 1
- 229920003123 carboxymethyl cellulose sodium Polymers 0.000 description 1
- 229940063834 carboxymethylcellulose sodium Drugs 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 229960001681 croscarmellose sodium Drugs 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 208000033679 diabetic kidney disease Diseases 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000007580 dry-mixing Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000012149 elution buffer Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N ethylene glycol Natural products OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- FETSQPAGYOVAQU-UHFFFAOYSA-N glyceryl palmitostearate Chemical compound OCC(O)CO.CCCCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCCCCCC(O)=O FETSQPAGYOVAQU-UHFFFAOYSA-N 0.000 description 1
- 229940046813 glyceryl palmitostearate Drugs 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- KHLVKKOJDHCJMG-QDBORUFSSA-L indigo carmine Chemical compound [Na+].[Na+].N/1C2=CC=C(S([O-])(=O)=O)C=C2C(=O)C\1=C1/NC2=CC=C(S(=O)(=O)[O-])C=C2C1=O KHLVKKOJDHCJMG-QDBORUFSSA-L 0.000 description 1
- 229960003988 indigo carmine Drugs 0.000 description 1
- 235000012738 indigotine Nutrition 0.000 description 1
- 239000004179 indigotine Substances 0.000 description 1
- 229960001021 lactose monohydrate Drugs 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 238000003801 milling Methods 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 201000003142 neovascular glaucoma Diseases 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 229920001993 poloxamer 188 Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 208000037803 restenosis Diseases 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Definitions
- the present invention relates to a method for preparing a pharmaceutical composition comprising a triazolopyrazine derivative represented by the following Chemical Formula 1 as an active ingredient in a tablet formulation.
- the present invention relates to a method for preparing a tablet tablet of a pharmaceutical composition comprising a triazolopyrazine derivative (ABN401) represented by the following formula (1) as an active ingredient.
- a triazolopyrazine derivative (ABN401) represented by the following formula (1) as an active ingredient.
- a drug delivery system is a method of designing a drug formulation or drug delivery method to minimize side effects and maximize pharmacological action by selectively delivering drugs to necessary parts of the body or to specific disease areas. means technology.
- Such DDS may be classified into a sustained release (SR) system, an immediate release (IR) system, a controlled release (CR) system, a targeted DDS, and the like.
- the SR system is a formulation designed to minimize these problems by slowing the release rate of the drug when the bioavailability is low, the absorption of the drug is too slow, or the loss rate of the drug is high.
- the IR system has a relatively short duration of drug release compared to the SR system, but increases the bioavailability by increasing the release rate per unit time.
- triazolopyrazine and its derivatives which are compounds having inhibitory activity on tyrosine kinase, and using them, various hyperproliferative disorders caused by abnormal tyrosine kinase activity can be effectively treated can be prevented or treated with
- flowability and tabletting properties were very poor due to a high content and a large amount of fine powder.
- the researchers of the present invention have a triazolopyrazine derivative compound represented by Formula 1, microcrystalline cellulose (MCC) as a main component as a binder, and low-substituted hydroxypropyl cellulose as a disintegrant ; LH21) and mannitol and floxamer (Kolliphor P188) as additives were confirmed to improve drug flow, dissolution rate, and mixing uniformity, and the present invention was completed.
- MMC microcrystalline cellulose
- LH21 low-substituted hydroxypropyl cellulose
- Kolliphor P188 mannitol and floxamer
- the compound of Formula 1 (ABN401) binds to hepatocyte growth factor (HGF) and inactivates phosphorylation, thereby triggering cell proliferation, migration, and formation of new blood vessels. It is known to significantly inhibit the activity.
- HGF hepatocyte growth factor
- hypo proliferative disorder refers to a pathological condition caused by excessive cell growth, division, and migration that is not controlled by general limiting means in a normally growing animal.
- Dysproliferative diseases to be prevented or treated with the composition of the present invention include, for example, cancer, diabetic retinopathy, retinopathy of prematurity, corneal transplant rejection, neovascular glaucoma, erythematosus, proliferative retinopathy, psoriasis, rheumatoid arthritis, osteoarthritis, autoimmune disease.
- cancer which is one of the dysproliferative diseases that can be prevented and treated by the composition of the present invention, is lung cancer, stomach cancer, pancreatic cancer, colorectal cancer, ovarian cancer, renal cell cancer, prostate cancer or liver cancer.
- An object of the present invention is to provide a method for preparing a pharmaceutical composition containing a zolopyrazine derivative as an active ingredient into a tablet tablet.
- the present invention solves problems such as tableting disorder and non-uniformity in content due to the poor flowability and tabletting property of the triazolopyrazine derivative (ABN401) represented by Formula 1 by manufacturing a tablet prepared by including the additive provided in the present invention.
- the usefulness of the compound can be further improved.
- 1 is a schematic diagram of the manufacturing process of the tablet tablet of the drug provided in the present invention.
- the present invention prepares a pharmaceutical composition comprising the compound of Formula 1 (ABN401) as an active ingredient, which can effectively prevent or treat various hyper proliferative disorders by inhibiting the activity of c-Met kinase, in tablet form it's about how to
- the present invention relates to a method for preparing a tablet of a pharmaceutical composition comprising the triazolopyrazine derivative (ABN401) represented by Formula 1 as an active ingredient, and to a tablet prepared by the method.
- ABS401 triazolopyrazine derivative
- the method for preparing a tablet tablet of a drug containing the triazolopyrazine derivative as an active ingredient to be provided in the present invention comprises the following steps.
- the tablet tablet manufacturing method provided in the present invention is specifically
- the binder used in the first and second steps of the present invention is microcrystalline cellulose, mannitol, low-substituted hydroxypropylcellulose (L-HPC, LH21), poloxamer (Kolliphor, P188), sodium stearyl fumarate, lactose monohydrate, sorbitol, and one or more components selected from sucrose may be included.
- the weight ratio of the triazolopyrazine derivative and the binder may be 20:0.1 to 50:5.
- a binding solution may be further added, and purified water may be used as the binding solution.
- the disintegrant of the present invention may be any one or more selected from methyl cellulose, crospovidone, alginic acid, croscarmellose, sodium starch glycolate and carboxymethyl cellulose.
- the weight ratio of the triazolopyrazine derivative and the disintegrant may be 20:0.1 to 50:5.
- the tablet tablet of the present invention may further include an excipient in addition to the binder and disintegrant.
- the excipient used in the present invention is an additive used in the development of drug formulations such as lubricants, surfactants, and glidants.
- Colloidal silicon dioxide, magnesium trisilicate, corn starch, talc, carboxymethyl cellulose sodium, croscarmel Croscarmellose Sodium, Povidone K30, Povidone K90, Polyethylene Glycol, Polyethylene Oxide, Polyethylenepropylene Glycol Copolymer, Glyceryl Monostearate, Glyceryl Palmitostearate, Glyceryl Behenate may include any one or more selected from the group consisting of ethyl maltol, wax, sodium acetate trihydrate, and the like.
- the weight ratio of the triazolopyrazine derivative to the excipient may be 25:55 to 50:70.
- Opadry As a coating agent used in the coating step, which is the fifth step of the manufacturing method provided in the present invention, Opadry may be used.
- the Opadry is a widely used stability-proven coating agent for coating a drug manufactured in a solid form manufactured by Calacon, and can improve the hygroscopicity, photostability, etc. of the tablet tablet.
- the Opadry is prepared by mixing polyvinyl alcohol, polyethylene glycol, titanium oxide, indigo carmine aluminum cake, and the like, and a colorant compound such as brilliant blue may be added in addition to the above ingredients according to the color of the surface of the drug.
- a high-shear granulator of Gerteis Minipactor was used, and the step of preparing granules using the high-shear granulator was performed at an impeller speed of 400rpm to 12000rpm, and the amount of the binder solution sprayed was 25 ul/ It may be s to 75ul/s, and preferably, the amount of the binding solution sprayed at an impeller speed of 500rpm to 12000rpm may be 50ul/s to 250ul/s.
- the drying of the granules may be performed in a fluidized bed dryer.
- the fluidized bed dryer is used for dry mixing of powders, fine grains, and granules of pharmaceutical, chemical, food, etc., and is a device that loads the object to be dried in a container, floats to the top with heated air, and dries while flowing.
- the compression step a Beta Press SADE rotary tablet compressor was applied, and a pressure of 1 to 10 kN/cm may be applied.
- the coating step O'Hara Lab Coat was used, and a fan speed of 10 to 30 rpm can be applied.
- Example 1 Preparation of various tablet tablets containing ABN401 as an active ingredient
- ABN401 excipients
- binders and disintegrants were placed in a high-shear granulator and mixed at a rotation speed of 500 rpm for 5 minutes.
- Granules were prepared while mixing the mixture at 800 rpm for 4 minutes while adding purified water at a rate of 1 ml per 20 seconds until granules were formed.
- the prepared granules were dried in an oven at 60° C. for about 1 hour and 30 minutes.
- the dried granules were sieved using a No. 25 sieve, the type and content of the disintegrant for post-mixing described above were added as much as the formulation amount, and the mixture was mixed for about 5 minutes.
- Example 1 (5 mg)
- Example 2 25 mg
- Example 3 100 mg
- Example 4 200 mg
- Sodium lauryl sulphate 6.45 32.25 - - Sodium Starch Glycolate 3.3 16.50 48.75 97.50
- Colloidal silicon dioxide 0.60 3.00 6.00 6.00
- Sodium Stearyl fumarate 0.30 1.50 3.0 6.00
- Opadry 1.80 9.0 9.0 18.00
- the dissolution rate of the tablet tablet drug of the present invention was measured by using the HPLC method.
- Example 1 Example 2
- Example 3 Example 4
- Mean %RSD Mean %RSD Mean %RSD Mean %RSD 5 89 5.7 100 3.1 37 19.2 23 8.8 10
- 88 7.0 30
- 45 105 5.2 106 2.0
- Example 1 Example 2
- Example 3 Example 4 Thickness (mm) 2.45 -2 .65 3.76 - 12.90 3.96 - 4.42 5.33 - 5.62
- Intensity (kP) 3.30 - 9.90 3.63 - 7.00 4.80 - 14.70 13.50 - 24.50
- the tablet tablet containing the triazolopyrazine derivative represented by Formula 1 provided by the present invention from the above Examples and Experimental Examples as an immediate release drug formulation for oral administration was found to be suitable as
- the present invention is industrially applicable.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
성분 | 실시예1(5mg) | 실시예2(25mg) | 실시예3(100mg) | 실시예4(200mg) |
ABN401 | 5.00 | 25.00 | 100.00 | 200.00 |
Mannitol | 16.80 | 84.00 | 30.99 | 61.98 |
MCC | 23.35 | 116.76 | 85.02 | 170.04 |
L-HPC | 3.60 | 18.00 | 26.25 | 52.50 |
Kolliphor | 0.60 | 3.00 | 3.00 | 6.00 |
Sodium lauryl sulphate | 6.45 | 32.25 | - | - |
Sodium Starch Glycolate | 3.3 | 16.50 | 48.75 | 97.50 |
Colloidal silicon dioxide | 0.60 | 3.00 | 6.00 | 6.00 |
Sodium Stearyl fumarate | 0.30 | 1.50 | 3.0 | 6.00 |
Opadry | 1.80 | 9.0 | 9.0 | 18.00 |
시간(분) | 실시예 1 | 실시예 2 | 실시예 3 | 실시예 4 | ||||
Mean | % RSD | Mean | % RSD | Mean | % RSD | Mean | % RSD | |
5 | 89 | 5.7 | 100 | 3.1 | 37 | 19.2 | 23 | 8.8 |
10 | 110 | 4.9 | 104 | 2.0 | 82 | 20.0 | 45 | 6.5 |
20 | 109 | 5.3 | 105 | 2.1 | 103 | 1.5 | 88 | 7.0 |
30 | 108 | 5.1 | 106 | 2.1 | 105 | 0.9 | 101 | 1.8 |
45 | 105 | 5.2 | 106 | 2.0 | 105 | 0.8 | 102 | 2.5 |
infinity | 105 | 5.4 | 106 | 2.0 | 105 | 0.7 | 104 | 1.6 |
실시예 1 | 실시예 2 | 실시예 3 | 실시예 4 | |
두께(mm) | 2.45 -2 .65 | 3.76 - 12.90 | 3.96 - 4.42 | 5.33 - 5.62 |
강도(kP) | 3.30 - 9.90 | 3.63 - 7.00 | 4.80 - 14.70 | 13.50 - 24.50 |
Claims (10)
- 제 1 항에 있어서, 상기 결합제는 미결정셀룰로스, 만니톨, 저치환도히드록시프로필셀룰로오스, 폴록사머, 소디움스테아릴푸마레이트, 락토오즈, 전분, 소비톨 및 수크로스로 이루어지는 군에서 선택되는 하나 이상인 것을 특징으로 하는 태블릿 제형 조성물
- 제 1 항에 있어서, 상기 붕해제는 메틸셀룰오스, 크로스포비돈, 알긴산, 크로스카멜로오스, 소디움스타치글리코네이트 및 카르복시메틸셀룰로오스로 이루어지는 군에서 선택되는 어느 하나 이상인 것을 특징으로 하는 태블릿 제형 조성물
- 제 1 항에 있어서, 상기 부형제는 콜로이드 이산화규소, 마그네슘트리실리케이트, 옥수수 전분, 탈크, 카복시메틸셀룰로스나트륨, 크로스카멜로스나트륨, 포비돈, 폴리에틸렌글리콜, 폴리에틸렌프로필렌글리콜 코폴리머, 글리세릴 모노스테아레이트, 글리세릴 팔미토스테아레이트, 글리세릴 베헤네이트, 에틸말톨, 왁스 및 소듐아세테이트트리하이드레이트로 이루어지는 군에서 선택되는 어느 하나 이상인 것을 특징으로 하는 태블릿 제형 조성물
- 제1항에 있어서, 상기 이상증식성 질환은 폐암, 위암, 췌장암, 대장암, 난소암, 신장 세포암, 전립선암 및 간암 중에서 선택되는 어느 하나인 것을 특징으로 하는 태블릿 제형 조성물
- 하기의 화학식 1로 표현되는 트리아졸로피라진 유도체, 결합제, 붕해제 및 부형제를 포함하는 형성되는 이상증식성 질환의 치료를 위한 태블릿 제형의 조성물을 제조하는 방법에 관한 것으로서, 상기 제조방법은 다음의 단계를 포함하여 이루어지며,<화학식 1>화학식 1의 트리아졸로피라진 유도체와 붕해제, 결합제 및 부형제를 혼합 및 연합하는 제1단계;상기 제1단계의 조성물에 결합제를 더 추가하여 과립공정을 거쳐서 과립을 제조하는 제2단계;상기 제2단계에서 제조된 조성물에 붕해제를 더 추가하여 혼합하는 제3단계;상기 제3단계를 거친 조성물을 압축하는 제4단계;상기 제4단계를 거친 조성물을 코팅하는 제5단계.상기 트리아졸로피라진 유도체와 결합제의 중량비는 20:0.1 내지 50:5이고,상기 트리아졸로피라진 유도체와 붕해제의 중량비는 20:0.1 내지 50:5이고,상기 트리아졸로피라진 유도체와 부형제의 중량비는 25:55 내지 50:70인 것을 특징으로 하는 태블릿 제형의 조성물을 제조하는 방법
- 제 6 항에 있어서, 상기 결합제는 미결정셀룰로스, 만니톨, 저치환도히드록시프로필셀룰로오스, 폴록사머, 소디움스테아릴푸마레이트, 락토오즈, 전분, 소비톨 및 수크로스로 이루어지는 군에서 선택되는 하나 이상인 것을 특징으로 하는 태블릿 제형의 조성물의 제조하는 방법
- 제 6 항에 있어서, 상기 붕해제는 메틸셀룰오스, 크로스포비돈, 알긴산, 크로스카멜로오스, 소디움스타치글리코네이트 및 카르복시메틸셀룰로오스로 이루어지는 군에서 선택되는 어느 하나 이상인 것을 특징으로 하는 태블릿 제형의 조성물의 제조하는 방법
- 제 6 항에 있어서, 상기 부형제는 콜로이드 이산화규소, 마그네슘트리실리케이트, 옥수수 전분, 탈크, 카복시메틸셀룰로스나트륨, 크로스카멜로스나트륨, 포비돈, 폴리에틸렌글리콜, 폴리에틸렌프로필렌글리콜 코폴리머, 글리세릴 모노스테아레이트, 글리세릴 팔미토스테아레이트, 글리세릴 베헤네이트, 에틸말톨, 왁스 및 소듐아세테이트트리하이드레이트로 이루어지는 군에서 선택되는 어느 하나 이상인 것을 특징으로 하는 태블릿 제형의 조성물의 제조하는 방법
- 제 6 항에 있어서, 상기 제5단계인 코팅단계에서 사용되는 코팅제는 오파드라이인 것을 특징으로 하는 태블릿 제형의 조성물을 제조하는 방법
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202180084970.2A CN116583288A (zh) | 2021-01-08 | 2021-01-19 | 包含三唑并吡嗪衍生物化合物作为有效成分的药物组合物的片剂的制备方法 |
US18/267,459 US20240058273A1 (en) | 2021-01-08 | 2021-01-19 | Method for preparing pharmaceutical formulation of tablet containing trizolopyrazine derivative as an active ingredient |
JP2023540100A JP2024501691A (ja) | 2021-01-08 | 2021-01-19 | トリアゾロピラジン誘導体化合物を有効成分とする薬学的組成物のタブレット錠の製造方法 |
EP21917810.0A EP4275678A1 (en) | 2021-01-08 | 2021-01-19 | Method for preparing tablet of pharmaceutical composition comprising triazolopyrazine derivative compound as active ingredient |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2021-0002315 | 2021-01-08 | ||
KR1020210002315A KR102659095B1 (ko) | 2021-01-08 | 2021-01-08 | 트리아졸로피라진 유도체 화합물을 유효성분으로 하는 약학적 조성물의 태블릿정의 제조방법 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2022149647A1 true WO2022149647A1 (ko) | 2022-07-14 |
Family
ID=82357163
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2021/000759 WO2022149647A1 (ko) | 2021-01-08 | 2021-01-19 | 트리아졸로피라진 유도체 화합물을 유효성분으로 하는 약학적 조성물의 태블릿정의 제조방법 |
Country Status (6)
Country | Link |
---|---|
US (1) | US20240058273A1 (ko) |
EP (1) | EP4275678A1 (ko) |
JP (1) | JP2024501691A (ko) |
KR (1) | KR102659095B1 (ko) |
CN (1) | CN116583288A (ko) |
WO (1) | WO2022149647A1 (ko) |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004052342A1 (en) * | 2002-12-09 | 2004-06-24 | Astrazeneca Ab | A new oral immediated release dosage form |
US8507487B2 (en) | 2009-12-31 | 2013-08-13 | Hutchison Medipharma Limited | Certain triazolopyridines and triazolopyrazines, compositions thereof and methods of use therefor |
KR20140140353A (ko) * | 2013-05-29 | 2014-12-09 | 주식회사 바이오파마티스 | 안정성 및 약물상호작용이 개선된 경구용 복합 정제 조성물 |
KR101745741B1 (ko) * | 2012-08-13 | 2017-06-12 | 한국화학연구원 | 신규한 트리아졸로 피라진 유도체 및 그의 용도 |
KR20190028903A (ko) * | 2017-09-11 | 2019-03-20 | 에이비온 주식회사 | 트리아졸로피라진계 화합물, 결합제 및 붕해제를 포함하는 속방형 캡슐제 조성물 |
-
2021
- 2021-01-08 KR KR1020210002315A patent/KR102659095B1/ko active IP Right Grant
- 2021-01-19 US US18/267,459 patent/US20240058273A1/en active Pending
- 2021-01-19 CN CN202180084970.2A patent/CN116583288A/zh active Pending
- 2021-01-19 EP EP21917810.0A patent/EP4275678A1/en active Pending
- 2021-01-19 WO PCT/KR2021/000759 patent/WO2022149647A1/ko active Application Filing
- 2021-01-19 JP JP2023540100A patent/JP2024501691A/ja active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004052342A1 (en) * | 2002-12-09 | 2004-06-24 | Astrazeneca Ab | A new oral immediated release dosage form |
US8507487B2 (en) | 2009-12-31 | 2013-08-13 | Hutchison Medipharma Limited | Certain triazolopyridines and triazolopyrazines, compositions thereof and methods of use therefor |
KR101745741B1 (ko) * | 2012-08-13 | 2017-06-12 | 한국화학연구원 | 신규한 트리아졸로 피라진 유도체 및 그의 용도 |
KR20140140353A (ko) * | 2013-05-29 | 2014-12-09 | 주식회사 바이오파마티스 | 안정성 및 약물상호작용이 개선된 경구용 복합 정제 조성물 |
KR20190028903A (ko) * | 2017-09-11 | 2019-03-20 | 에이비온 주식회사 | 트리아졸로피라진계 화합물, 결합제 및 붕해제를 포함하는 속방형 캡슐제 조성물 |
Non-Patent Citations (1)
Title |
---|
KIM JOOSEOK, PARK KYUNG EUI, JEONG YOO-SEONG, KIM YEONGMUN, PARK HAYEON, NAM JI-HYE, JUNG KYUNGSOO, SON WOO SUNG, JUNG HUN SOON, L: "Therapeutic Efficacy of ABN401, a Highly Potent and Selective MET Inhibitor, Based on Diagnostic Biomarker Test in MET-Addicted Cancer", CANCERS, vol. 12, no. 6, 1 January 2020 (2020-01-01), pages 1 - 23, XP055950004, DOI: 10.3390/cancers12061575 * |
Also Published As
Publication number | Publication date |
---|---|
US20240058273A1 (en) | 2024-02-22 |
CN116583288A (zh) | 2023-08-11 |
EP4275678A1 (en) | 2023-11-15 |
KR20220100184A (ko) | 2022-07-15 |
JP2024501691A (ja) | 2024-01-15 |
KR102659095B1 (ko) | 2024-04-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11786470B2 (en) | Solid pharmaceutical compositions and processes for their production | |
US20220267340A1 (en) | Dosage form compositions comprising an inhibitor of bruton's tyrosine kinase | |
EP2568988B1 (en) | Pharmaceutical formulations comprising 1-(beta-d-glucopyranosyl)-2-thienylmethylbenzene derivatives as inhibitors of sglt | |
CN109776432B (zh) | 一种多靶点激酶抑制剂、药物组合物及多靶点激酶抑制剂的制备方法和应用 | |
US20140341993A1 (en) | Solid pharmaceutical composition comprising an antibiotic from the quinolone family and method of production thereof | |
WO2020159117A1 (ko) | 피리도피리미딘계 염산염을 포함하는 경구용 고형제제 및 이의 제조방법 | |
WO2022149647A1 (ko) | 트리아졸로피라진 유도체 화합물을 유효성분으로 하는 약학적 조성물의 태블릿정의 제조방법 | |
CA2067275C (en) | Pharmaceutical formulation containing dirithromycin | |
WO2017116031A1 (ko) | 유당불내성 환자에게 투여가 가능하며, 복용편의성이 향상된 게피티니브를 함유하는 약제학적 조성물 | |
KR102389339B1 (ko) | 방출 제어되는 고함량 탐스로신 정제 조성물 및 이의 제조방법 | |
KR20220156930A (ko) | 무정형 3,4-디페닐-4,5-디하이드로-1h-피라졸 유도체의 고체 분산체, 이를 포함하는 조성물 및 칸나비노이드 cb1 수용체 억제제로서의 이의 용도 | |
WO2019139313A1 (en) | Stabilized pharmaceutical formulation comprising everolimus | |
WO2016195377A2 (ko) | 생체이용률이 개선된 프란루카스트 함유 고형 제제의 조성물 및 그 제조방법 | |
US20230119355A1 (en) | Pharmaceutical compositions of a kinase inhibitor | |
JP2018030810A (ja) | ゲフィチニブを有効成分とする医薬錠剤の製造方法 | |
JP6945377B2 (ja) | エルロチニブを有効成分とする医薬錠剤及びその製造方法 | |
WO2014038895A1 (ko) | 발사르탄 함유 고형 경구제형 및 그 제조방법 | |
JP3281872B2 (ja) | 7−イソインドリン−3−キノリンカルボン酸の塩、その水和物およびそれらを活性成分とする組成物 | |
CN114832112A (zh) | 含有alk激酶抑制剂的药物制剂组合物及其制备方法 | |
WO2019199135A1 (ko) | 레날리도마이드를 포함하는 경구용 고형제제의 제조방법 | |
WO2023113488A1 (en) | Pharmaceutical combination which has improved convenience for internal use through size reduction for formulation comprising dapagliflozin and sitagliptin and preparing method thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21917810 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 202180084970.2 Country of ref document: CN Ref document number: 18267459 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2023540100 Country of ref document: JP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2021917810 Country of ref document: EP Effective date: 20230808 |